Mark your calendars: 2 day-breast cancer meeting with Harvard Medical School Dana-Farber faculty led by Harold J. Burstein, MD, PhD, FASCO ! can't miss it!

cmecatalog.hms.harvard.edu/breast-cancer-…

Time of the year when in Boston is summer and you have the opportunity to attend the most comprehensive review of breast cancer treatment ⁦Harold J. Burstein, MD, PhD, FASCO⁩. In person or hybrid registration link 👇Breast Cancer: New Horizons, Current Controversies #bcsm cmecatalog.hms.harvard.edu/breast-cancer-…

Extremely important topic. Watching this 7 minutes video can empower your role and contribute to eliminate inequities for breast cancer treatment.
⬆️ early detection in developing countries
⬇️ educate disparities about cancer
⬇️ cost of life saving drugs in low income countries

What’s better than getting a new ACL on Patriots Day? I want to thank all nurses, anesthesia. Residents, and Dr. Lattermann’s team for the amazing care provided today. I promise will be back ⚽️ BWH Sports Med Brigham and Women's Hospital

Genomic spectrum of actionable alterations in serial cfDNA analysis of patients with MBC. New alterations with a potential impact on treatment selection continued to emerge, particularly for patients with HR+/HER2- #bcsm pubmed.ncbi.nlm.nih.gov/38605020/

The smile at the end 😄

Jannik Sinner #RolexMonteCarloMasters

Fantastic work looking at #tucatinib activity post #TDXd for #HER -2+ #bcsm . These real world looks at a drug's activity when sequencing is altered/new drugs are approved is important!

jamanetwork.com/journals/jaman…

Congratulations Hope Rugo for this career achievement #bcsm

The 3rd Transatlantic Exchange between Dana-Farber & Gustave Roussy in Oncology Conference is coming up with the topic of' Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine'

APRIL 12, 2024 | 8:00 AM - 4:15 PM ET (in-person in Boston and Virtual)

LINK:

🙌Just out on @JAMAonc our review on PARPi for #breastcancer
Many steps have been made in the last 20 yrs; a vast amount is left waiting to be explored.
Great team effort led by Dana-Farber’s Breast Oncology Center and IEO.
Link 👉 jamanetwork.com/journals/jamao…

The DF/HCC Breast Cancer Program holds yearly research retreats to pool diverse expertise and foster innovative research approaches. Read about our recent research retreat on cyclin-dependent kinases ( #CDKs ) in #BreastCancer here dfhcc.harvard.edu/news/detail?tx…
Antonio Giordano, MD PhD Geoffrey Shapiro MD PhD

Let's celebrate #RareDiseaseDay by racing toward a cure for Inflammatory Breast Cancer. Join Team IBC The Jimmy Fund to raise much needed funds for IBC research and patient care! danafarber.jimmyfund.org/goto/TeamIBC20…
Antonio Giordano, MD PhD Paolo Tarantino Laura Warren, MD Dana-Farber’s Breast Oncology Center Meredith Regan, ScD Filipa Lynce, MD, FASCO

True honor to have the opportunity of joining the outstanding faculty of #JSMO24 to review the many exciting targeted agents in development to better treat our patients with hormone receptor positive metastatic breast cancer. #bcsm Dana-Farber’s Breast Oncology Center 日本臨床腫瘍学会（JSMO）

#trialtuesday is Trial 23-044: STX-478 mutant-selective, PI3Kα small molecule inhibitor, highly selective for kinase and/or helical domain mutations in breast, gynecological, head and neck, and other solid tumors #CCTI_DFCI Dana-Farber Antonio Giordano, MD PhD
Visit: forms.office.com/r/kM7e6JVxre

Closer look to recurrences:

1. CNS remains a sanctuary for mets - high rate of 🧠
recurrence in pCR/RCB-I

2. EFS benefit from pembro exceeded that expected by the improvement in pCR alone and regardless of 🔢chemotherapy (full vs. < full)

3. higher local recurrence in RCB-III

FDA granted accelerated approval to lifileucel, a tumor-derived autologous T cell immunotherapy (CAR-T), for patients with unresectable or metastatic melanoma (solid tumor!) previously treated with a PD-1 blocking antibody and a BRAF inhibitor with or without a MEK inhibitor

Next up in our webinar series for people living with metastatic breast cancer - Please join us Feb 16th 12-1PM ET!

For #trialtuesday , #CCTI_DFCI presents new trial 23-600 led by Filipa Lynce, MD, FASCO. IDE161, a PARG inhibitor, targets HRD and BRCA mutations in ER+ breast, endometrial, colorectal, and head and neck with these mutations. Different from PARPi. Dana-Farber
Visit: forms.office.com/r/kM7e6JVxre

Dr. Glenn Hanna giving state-of-the-center for our early drug development program @danafarber_ccti 6-month tremendous growth - saying yes and saying no - to give patients more trial opportunities and treatment options. #phase1trial #CancerResearch Glenn J. Hanna, M.D.

Tk you @Thelancet for taking this question seriously. Academic clinical trials should be evaluated mainly based on their IMPACT on pts, not only on innovation. Too many grant committees give too much weight to innovation vs impact , when it’s about funding clinical trials